Demographic and clinical characteristics of the enrolled disease group subtypes
| HC (n = 73) | RRMS (n = 162) | SPMS (n = 66) | |
|---|---|---|---|
| Age, median (IQR) | 44 (17) | 44 (16) | 54.5 (9) |
| Sex | |||
| % Male | 45.2 | 22.8 | 19.7 |
| Male/female | 33/40 | 37/125 | 13/53 |
| EDSS, median (IQR) [# missing] | 2 (1.5) [8] | 6 (2) [2] | |
| Disease duration, years; median (IQR) | 9 (11) | 19.5 (18) |
Note:—Of the 228 patients with MS, 204 were on disease-modifying therapy. These included 68 patients on interferon beta-1a I.M., 23 on interferon beta 1a S.C., 1 on interferon beta 1b, 46 on glatiramer acetate, 50 on natalizumab, 3 on intravenous immunoglobulin, 4 on mycophenolate mofetil, 2 on azathioprine, 2 on combination therapy, and 1 on mitoxantrone; drug data for 4 patients were not recorded. IQR indicates interquartile range.